Evidence map›Paper›PMID 35178105›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Jie Zhu, Liqin Yu, Yi Fan, Huanan Zhang, Feifei Li, Xiao Li, Yue Wei, Zhiyao Wang

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Gut microbiota remodeling inZoological research · 2026
    Article
  3. Article
  4. Evaluation of the therapeutic effect ofFrontiers in immunology · 2025
    Article
  5. Article
  6. Heliyon · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jie ZhuHenan Napu Biotechnology Co., Ltd., Zhengzhou, Henan 450000, China.ORCID https://orcid.org/0000-0001-6519-9362
Liqin YuHenan Napu Biotechnology Co., Ltd., Zhengzhou, Henan 450000, China.
Yi FanHenan Napu Biotechnology Co., Ltd., Zhengzhou, Henan 450000, China.ORCID https://orcid.org/0000-0002-0053-8105
Huanan ZhangHenan Napu Biotechnology Co., Ltd., Zhengzhou, Henan 450000, China.
Feifei LiHenan Napu Biotechnology Co., Ltd., Zhengzhou, Henan 450000, China.
Xiao LiHenan Napu Biotechnology Co., Ltd., Zhengzhou, Henan 450000, China.
Yue WeiHenan Napu Biotechnology Co., Ltd., Zhengzhou, Henan 450000, China.
Zhiyao WangHenan Napu Biotechnology Co., Ltd., Zhengzhou, Henan 450000, China.
Henan Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diarrhea, occurring due to intestinal flora disturbance, is potentially lethal, and its current treatments have adverse effects such as constipation and vomiting.

Identifiers

PMID35178105
PMCPMC8846971
OpenAlexW4210886908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.